Overview

A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

Status:
RECRUITING
Trial end date:
2027-09-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the efficacy and safety of AZD0901 monotherapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Phase:
PHASE2
Details
Lead Sponsor:
AstraZeneca